The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Bayer; Blueprint Medicines; Bristol-Myers Squibb; Eisai; Ipsen
Travel, Accommodations, Expenses - Bayer; Blueprint Medicines; Bristol-Myers Squibb; Can-Fite BioPharma; Celsion; Eisai; Fortress Biotech; Glycotest; Ipsen; Leerink; Lilly; Merck; Midatech Pharma; Navigant Consulting; Nucleix; Spring Bank; Xelixis
Ramucirumab in patients with advanced HCC and elevated alpha-fetoprotein (AFP): Outcomes by treatment-emergent ascites.
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Exelixis; Lilly; Merck; Roche/Genentech
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Masafumi Ikeda
Honoraria - Astellas Pharma; Bayer Yakuhin; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Gilead Sciences; Kaken Pharmaceutical; Lilly Japan; MSD; Mylan; Novartis; Otsuka; SERVIER; Taiho Pharmaceutical; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Micron; MSD; Novartis; Ono Pharmaceutical; SERVIER; Shire; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Peter R. Galle
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Lilly; Merck; Novartis; Roche; Sillajen; Sirtex Medical
 
Tatsuya Yamashita
Speakers' Bureau - Bayer; Eisai; Lilly
 
Josep Llovet
No Relationships to Disclose
 
Kun Liang
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Chunxiao Wang
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Sachi Sakaguchi
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Paolo Abada
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Ryan C Widau
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Masatoshi Kudo
Honoraria - Bayer; Eisai; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; MSD; Ono Pharmaceutical
Research Funding - Abbvie (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)